Malegra DXT (sildenafil + duloxetine)
Historical Sunrise Malegra DXT and DXT Plus: distinct duloxetine amounts, current identity limits and why daily PE research does not validate the combination.
- Active ingredients
- Sildenafil + Duloxetine
- Form
- Tablet
- Historical association
- Sunrise Remedies (archived company catalogue)
Malegra DXT has a documented historical Sunrise Remedies association. A company catalogue preserved on a marketplace lists sildenafil 100 mg plus duloxetine 30 mg for DXT, and sildenafil 100 mg plus duloxetine 60 mg for DXT Plus. The difference is a named variant, not simply a disagreement over one product’s amount.
Historical evidence is still evidence
The mirrored catalogue’s internal creation metadata predates its 2022 upload path. It is not a current manufacturer-hosted record, and the DXT names were not found in the current Sunrise ED/PE catalogue checked here. We therefore retain the historical company association while leaving current formulation and supply unconfirmed.
Plain Malegra remains in the current sildenafil family. DXT adds duloxetine, an SNRI whose PE research context is off-label in the checked reference information. That second ingredient changes the assessment substantially.
The research does not validate the combination tablet
A small duloxetine PE trial studied daily treatment followed by tapering, with significant patient loss to follow-up. It did not study Malegra DXT, its release design or an occasional combined tablet. The trial’s timing improvement should not be advertised as this product’s proven result.
Reference duloxetine products also have gastro-resistant or delayed-release formulation requirements. The exact combination’s release characteristics need evidence rather than an assumption based on the word “tablet.” Existing antidepressants, serotonergic interactions, blood pressure and stopping treatment all require review. Historical product identity is useful; it does not replace that clinical and formulation assessment.
Historically documented DXT presentations
Historical composition and company association; current formulation and authorization not established by this mirror.
| Name | Form | Strength |
|---|---|---|
| Malegra DXT | Tablet (historical catalogue) | Sildenafil 100 mg + duloxetine 30 mg |
| Malegra DXT Plus | Tablet (historical catalogue) | Sildenafil 100 mg + duloxetine 60 mg |
Product record
- Company
- Historical Sunrise Remedies catalogue; current exact listing not confirmed
- Strengths listed
- DXT: sildenafil 100 mg + duloxetine 30 mg; DXT Plus: sildenafil 100 mg + duloxetine 60 mg (historical catalogue)
- Treatment area
- ED component; PE marketed/research context for partner antidepressant, not a licensed PE claim for this combination
- Identity
- Historical company association documented; not found in current Sunrise ED/PE catalogue checked
- Record reviewed
- 4 October 2026; source retrieval dates are retained with the evidence
Listed strengths identify a product; they are not dosing advice. A listing in one country does not show that a product is authorized where you live.
About sildenafil
Sildenafil supports the erection response to stimulation. Food can delay absorption of ordinary film-coated tablets; blood half-life is not a guaranteed response window. Timed follow-up can help explain an apparent nonresponse.
About duloxetine
Duloxetine is an SNRI with a small daily-treatment PE study and important limitations. That study did not test Malegra DXT. Sexual adverse effects, blood pressure, interacting medicines and discontinuation require product-specific review.
About unverified names
This profile has historical, supplier or incomplete identity evidence. Some names have a company catalogue association; others have secondary listings with unresolved details. Read the exact source and remaining gap rather than assuming every unfamiliar name has no company evidence.
About fixed combinations
A fixed combination puts two medicines in one tablet at set doses. Each ingredient brings its own side effects and interactions, and approval of each ingredient on its own does not mean the combination is approved or suitable.
Do not add another ED or PE medicine to a combination product.
Using a PDE5 inhibitor safely
Never take a PDE5 inhibitor with nitrates, recreational nitrites (“poppers”) or riociguat, and do not combine two ED medicines. Seek urgent medical help for chest pain, an erection lasting more than four hours, or sudden loss of vision or hearing.
Common side effects include headache, flushing, indigestion and a blocked nose.
Sources
5 sources
Checked .
- VIAGRA (sildenafil) US prescribing information — DailyMed, US National Library of Medicine. Ingredient reference; it does not describe this brand.
- CYMBALTA (duloxetine) US prescribing information — DailyMed, US National Library of Medicine. Ingredient reference; it does not describe this brand.
- Historical Sunrise catalogue (marketplace-hosted mirror) — Sunrise Remedies catalogue mirror. Historical identity evidence; not a current company-hosted registration or listing.
- Current ED and PE company catalogue — Sunrise Remedies
- Duloxetine UK reference information — emc. Partner ingredient context, not a label for this fixed combination.